



NATIONAL QUALITY FORUM

Driving measurable health
improvements together

Memo

August 11, 2021

To: NQF members

From: NQF staff

Re: Renal Spring 2021 CDP Report

Background

This report reflects the review of measures in the Renal project. Measures in this portfolio address conditions, treatments, interventions, or procedures relating to kidney disease, a leading cause of morbidity and mortality in the United States (U.S.). Considering the high mortality rates and high healthcare utilization and costs associated with end-stage renal disease (ESRD), there is a significant need for quality measures for patients with renal disease.

The 25-person Renal Standing Committee reviewed two new measures. The Standing Committee did not recommend either measure for endorsement.

Measures Not Recommended:

- **NQF #3615** Unsafe Opioid Prescriptions at the Prescriber Group Level (Centers for Medicare & Medicaid Services CMS/University of Michigan Kidney Epidemiology and Cost Center (UMKECC))
- **NQF #3616** Unsafe Opioid Prescriptions at the Dialysis Practitioner Group Level (CMS/UMKECC)

The Standing Committee requests comments on all measures., but specifically for the measures where consensus was not reached.

NQF Member and Public Commenting

NQF members and the public are encouraged to provide comments via the online commenting tool on the draft report as a whole, or on the specific measures evaluated by the Renal Standing Committee.

Please note that commenting concludes on September 9, 2021 at 6:00 pm ET—no exceptions.